Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication

Clinical Neuropharmacology

Volumn 24, Issue 5, 2001, Pages 290-294

  Drapalski, Amy L ^a   Rosse, Richard B ^a,b   Peebles, Roger R ^a,b   Schwartz, Barbara L ^a,b   Marvel, Cherie L ^a,b   Deutsch, Stephen I ^a,b,c  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Excitotoxicity; Glutamate; Negative symptoms; Schizophrenia

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CYCLOSERINE; CYTOCHROME P450; GABAPENTIN; GLYCINE; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TOPIRAMATE;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; MALE; MENTAL DISEASE; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034812064     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200109000-00006     Document Type: Article

References (19)

1. Thought disorder, working memory and attention: Interrelationship and the effects of neuroleptic medications
2. A separate disease within the syndrome of schizophrenia
3. The glutamatergic dysfunction hypothesis for schizophrenia
4. A "glutamatergic hypothesis" of schizophrenia: Rationale for pharmacotherapy with glycine
5. Schizophrenia and glutamatergic transmission
6. The glutamate synapse in neuropsychiatric disorders
7. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
8. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
9. An open-label trial of milacemide in schizophrenia: An NMDA intervention strategy
10. An NMDA intervention strategy in schizophrenia with "low dose" milacemide
11. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia
12. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
13. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
14. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action
15. The positive and negative syndrome scale (PANSS) for schizophrenia
16. A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications
17. A mechanistic approach to antiepileptic drug interactions